A phase 2 study of decitabine with or without carboplatin and arsenic trioxide in patients with MDS and AML

Authors: Kropf, Patricia L. ^{1, 2, ∗}, Chung, Woonbok ^{3, 4}, Shameem, Raji ⁵, Xiao, Lianchun ⁶, Balch, Curt ⁴, Huang, Xuelin ⁶, Issa, Jean-Pierre J. ^{3, 4}

Source: In Blood Neoplasia December 2024

Guadecitabine vs treatment choice in newly diagnosed acute myeloid leukemia: a global phase 3 randomized study

Authors: Fenaux, Pierre, Gobbi, Marco, Kropf, Patricia L., Issa, Jean-Pierre J., Roboz, Gail J., Mayer, Jiri, Krauter, Jürgen, Robak, Tadeusz, Kantarjian, Hagop, Novak, Jan, Jedrzejczak, Wieslaw. W., Thomas, Xavier, Ojeda-Uribe, Mario, Miyazaki, Yasushi, Min, Yoo Hong, Yeh, Su-Peng, Brandwein, Joseph, Gercheva-Kyuchukova, Liana, Demeter, Judit, Griffiths, Elizabeth, Yee, Karen, Döhner, Konstanze, Hao, Yong, Keer, Harold, Azab, Mohammad, Döhner, Hartmut

Source: In Blood Advances 12 September 2023 7(17):5027-5037

Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy

Authors: Zeidan, Amer M., Fenaux, Pierre, Gobbi, Marco, Mayer, Jiří, Roboz, Gail J., Krauter, Jürgen, Robak, Tadeusz, Kantarjian, Hagop M., Novák, Jan, Jedrzejczak, Wieslaw W., Thomas, Xavier, Ojeda-Uribe, Mario, Miyazaki, Yasushi, Min, Yoo Hong, Yeh, Su-Peng, Brandwein, Joseph M., Gercheva, Liana, Demeter, Judit, Griffiths, Elizabeth A., Yee, Karen W.L., Issa, Jean-Pierre J., Bewersdorf, Jan Philipp, Keer, Harold, Hao, Yong, Azab, Mohammad, Döhner, Hartmut

Source: Blood. 140(3):285-289

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100183235899.0x000001&indx=1&recIds=ETOCvdc_100183235899.0x000001

High folic acid intake increases methylation-dependent expression of Lsr and dysregulates hepatic cholesterol homeostasis

Authors: Leclerc, Daniel, Jelinek, Jaroslav, Christensen, Karen E., Issa, Jean-Pierre J., Rozen, Rima

Source: In The Journal of Nutritional Biochemistry February 2021 88

Guadecitabine (SGI-110) in patients with intermediate or high-risk myelodysplastic syndromes: phase 2 results from a multicentre, open-label, randomised, phase 1/2 trial

Authors: Garcia-Manero, Guillermo, Roboz, Gail, Walsh, Katherine, Kantarjian, Hagop, Ritchie, Ellen, Kropf, Patricia, O'Connell, Casey, Tibes, Raoul, Lunin, Scott, Rosenblat, Todd, Yee, Karen, Stock, Wendy, Griffiths, Elizabeth, Mace, Joseph, Podoltsev, Nikolai, Berdeja, Jesus, Jabbour, Elias, Issa, Jean-Pierre J, Hao, Yong, Keer, Harold N, Azab, Mohammad, Savona, Michael R

Source: In The Lancet Haematology June 2019 6(6):e317-e327

Targeting CDK9 Reactivates Epigenetically Silenced Genes in Cancer

Authors: Zhang, Hanghang, Pandey, Somnath, Travers, Meghan, Sun, Hongxing, Morton, George, Madzo, Jozef, Chung, Woonbok, Khowsathit, Jittasak, Perez-Leal, Oscar, Barrero, Carlos A., Merali, Carmen, Okamoto, Yasuyuki, Sato, Takahiro, Pan, Joshua, Garriga, Judit, Bhanu, Natarajan V., Simithy, Johayra, Patel, Bela, Huang, Jian, Raynal, Noël J.-M., Garcia, Benjamin A., Jacobson, Marlene A., Kadoch, Cigall, Merali, Salim, Zhang, Yi, Childers, Wayne, Abou-Gharbia, Magid, Karanicolas, John, Baylin, Stephen B., Zahnow, Cynthia A., Jelinek, Jaroslav, Graña, Xavier, Issa, Jean-Pierre J.

Source: In Cell 15 November 2018 175(5):1244-1258

Chromatin Immunoprecipitation Microarrays for Identification of Genes Silenced by Histone H3 Lysine 9 Methylation

Authors: Kondo, Yutaka, Shen, Lanlan, Yan, Pearlly S., Huang, Tim Hui-Ming, Issa, Jean-Pierre J., Jaenisch, Rudolf

Source: Proceedings of the National Academy of Sciences of the United States of America, 2004 May 01. 101(19), 7398-7403.

Access URL: https://www.jstor.org/stable/3371877

Epigenetic Inactivation of CHFR in Human Tumors

Authors: Toyota, Minoru, Sasaki, Yasushi, Satoh, Ayumi, Ogi, Kazuhiro, Kikuchi, Takefumi, Suzuki, Hiromu, Mita, Hiroaki, Tanaka, Nobuyuki, Itoh, Fumio, Issa, Jean-Pierre J., Jair, Kam-Wing, Schuebel, Kornel E., Imai, Kohzoh, Tokino, Takashi

Source: Proceedings of the National Academy of Sciences of the United States of America, 2003 Jun . 100(13), 7818-7823.

Access URL: https://www.jstor.org/stable/3139830

Guadecitabine (SGI-110) in treatment-naive patients with acute myeloid leukaemia: phase 2 results from a multicentre, randomised, phase 1/2 trial

Authors: Kantarjian, Hagop M, Roboz, Gail J, Kropf, Patricia L, Yee, Karen W L, O'Connell, Casey L, Tibes, Raoul, Walsh, Katherine J, Podoltsev, Nikolai A, Griffiths, Elizabeth A, Jabbour, Elias, Garcia-Manero, Guillermo, Rizzieri, David, Stock, Wendy, Savona, Michael R, Rosenblat, Todd L, Berdeja, Jesus G, Ravandi, Farhad, Rock, Edwin P, Hao, Yong, Azab, Mohammad, Issa, Jean-Pierre J

Source: In The Lancet Oncology October 2017 18(10):1317-1326

Genome-wide screening and functional validation of methylation barriers near promoters.

Authors: Shu, Jingmin, Jelinek, Jaroslav, Chen, Hai, Zhang, Yan, Qin, Taichun, Li, Ming, Liu, Li, Issa, Jean-Pierre J

Source: Nucleic Acids Research; 5/22/2024, Vol. 52 Issue 9, p4857-4871, 15p

Distinct Genetic Profiles in Colorectal Tumors with or without the CpG Island Methylator Phenotype

Authors: Toyota, Minoru, Ohe-Toyota, Mutsumi, Ahuja, Nita, Issa, Jean-Pierre J.

Source: Proceedings of the National Academy of Sciences of the United States of America, 2000 Jan . 97(2), 710-715.

Access URL: https://www.jstor.org/stable/121687

CpG Island Methylator Phenotype in Colorectal Cancer

Authors: Toyota, Minoru, Ahuja, Nita, Ohe-Toyota, Mutsumi, Herman, James G., Baylin, Stephen B., Issa, Jean-Pierre J.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1999 Jul . 96(15), 8681-8686.

Access URL: https://www.jstor.org/stable/48546

The promise of epigenetic therapy: reprogramming the cancer epigenome

Authors: Kelly, Andrew D, Issa, Jean-Pierre J

Source: In Current Opinion in Genetics & Development February 2017 42:68-77

Incidence and Functional Consequences of hMLH1 Promoter Hypermethylation in Colorectal Carcinoma

Authors: Herman, James G., Umar, Asad, Polyak, Kornelia, Graff, Jeremy R., Ahuja, Nita, Issa, Jean-Pierre J., Markowitz, Sanford, Hamilton, Stanley R., Kinzler, Kenneth W., Kane, Michael F., Kolodner, Richard D., Vogelstein, Bert, Kunkel, Thomas A., Baylin, Stephen B.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1998 Jun 01. 95(12), 6870-6875.

Access URL: https://www.jstor.org/stable/45032

Digital Restriction Enzyme Analysis of Methylation (DREAM)

Authors: Jelinek, Jaroslav, Lee, Justin T., Cesaroni, Matteo, Madzo, Jozef, Liang, Shoudan, Lu, Yue, Issa, Jean-Pierre J.

Source: Methods in molecular biology. 1708:247-266

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN614480759&indx=1&recIds=ETOCRN614480759

Switch from Monoallelic to Biallelic Human IGF2 Promoter Methylation during Aging and Carcinogenesis

Authors: Issa, Jean-Pierre J., Vertino, Paula M., Boehm, Corinne D., Newsham, Irene F., Baylin, Stephen B.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1996 Oct . 93(21), 11757-11762.

Access URL: https://www.jstor.org/stable/40509

Increased Cytosine DNA-Methyltransferase Activity is Target-Cell-Specific and an Early Event in Lung Cancer

Authors: Belinsky, Steven A., Nikula, Kristen J., Baylin, Stephen B., Issa, Jean-Pierre J.

Source: Proceedings of the National Academy of Sciences of the United States of America, 1996 Apr . 93(9), 4045-4050.

Access URL: https://www.jstor.org/stable/39192

Zebrafish embryos as a screen for DNA methylation modifications after compound exposure

Authors: Bouwmeester, Manon C., Ruiter, Sander, Lommelaars, Tobias, Sippel, Josefine, Hodemaekers, Hennie M., van den Brandhof, Evert-Jan, Pennings, Jeroen L.A., Kamstra, Jorke H., Jelinek, Jaroslav, Issa, Jean-Pierre J., Legler, Juliette, van der Ven, Leo T.M.

Source: In Toxicology and Applied Pharmacology 15 January 2016 291:84-96

MC180295 is a highly potent and selective CDK9 inhibitor with preclinical in vitro and in vivo efficacy in cancer.

Authors: Zhang, Hanghang, Huang, Chen, Gordon, John, Yu, Sijia, Morton, George, Childers, Wayne, Abou-Gharbia, Magid, Zhang, Yi, Jelinek, Jaroslav, Issa, Jean-Pierre J.

Source: Clinical Epigenetics; 1/3/2024, Vol. 16 Issue 1, p1-14, 14p

Subject Terms: BLOOD cell count, RACEMIC mixtures, CYCLIN-dependent kinase inhibitors, CHROMATIN-remodeling complexes, T cells, DRUG toxicity

Safety and tolerability of guadecitabine (SGI-110) in patients with myelodysplastic syndrome and acute myeloid leukaemia: a multicentre, randomised, dose-escalation phase 1 study

Authors: Issa, Jean-Pierre J, Roboz, Gail, Rizzieri, David, Jabbour, Elias, Stock, Wendy, O'Connell, Casey, Yee, Karen, Tibes, Raoul, Griffiths, Elizabeth A, Walsh, Katherine, Daver, Naval, Chung, Woonbok, Naim, Sue, Taverna, Pietro, Oganesian, Aram, Hao, Yong, Lowder, James N, Azab, Mohammad, Kantarjian, Hagop

Source: In The Lancet Oncology September 2015 16(9):1099-1110